制药行业重磅交易：艾伯维以87亿美元收购Cerevel

金十数据2023-12-07

美国生物技术公司艾伯维(ABBV.N)将以87亿美元收购神经科学药物制造商Cerevel Therapeutics(CERE.O)，每股价格为45美元，较其周三的收盘价溢价22%。Cerevel成立于2018年，2020年上市，正在开发治疗阿尔茨海默病、精神病、癫痫、恐慌症和帕金森病等疾病的药物。艾伯维称，Cerevel“强大的”神经科学产品线有望为其增加改变精神科和神经系统疾病护理标准的药物。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2389601864?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-12-07 11:52","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2389601864","market":"us","top_or_hot":-1,"title":"制药行业重磅交易：艾伯维以87亿美元收购Cerevel","media":"金十数据","content":"<div>\n<p>美国生物技术公司艾伯维(ABBV.N)将以87亿美元收购神经科学药物制造商Cerevel Therapeutics(CERE.O)，每股价格为45美元，较其周三的收盘价溢价22%。Cerevel成立于2018年，2020年上市，正在开发治疗阿尔茨海默病、精神病、癫痫、恐慌症和帕金森病等疾病的药物。艾伯维称，Cerevel“强大的”神经科学产品线有望为其增加改变精神科和神经系统疾病护理标准的药物。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120711524683db7833&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>制药行业重磅交易：艾伯维以87亿美元收购Cerevel</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n制药行业重磅交易：艾伯维以87亿美元收购Cerevel\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-07 11:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120711524683db7833&s=b><strong>金十数据</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美国生物技术公司艾伯维(ABBV.N)将以87亿美元收购神经科学药物制造商Cerevel Therapeutics(CERE.O)，每股价格为45美元，较其周三的收盘价溢价22%。Cerevel成立于2018年，2020年上市，正在开发治疗阿尔茨海默病、精神病、癫痫、恐慌症和帕金森病等疾病的药物。艾伯维称，Cerevel“强大的”神经科学产品线有望为其增加改变精神科和神经系统疾病护理标准的药物。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120711524683db7833&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0820561909.HKD","symbol_name":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120711524683db7833&s=b","article_id":"2389601864","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120711524683db7833&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2389601864","pubTimestamp":1701921163,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"艾伯维称，Cerevel“强大的”神经科学产品线有望为其增加改变精神科和神经系统疾病护理标准的药物。艾伯维表示，两家公司的董事会已批准该交易，预计将于2024年中期完成，但仍须获得Cerevel股东的批准并满足其他成交条件。他还称，艾伯维将利用其深厚的商业能力、国际基础设施以及监管和临床专业知识，为Cerevel的资产组合提供巨大的股东价值和数十亿美元的销售潜力。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","ABBV":"艾伯维公司","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IMGN":"ImmunoGen","LU0122379950.USD":"贝莱德世界健康科学A2","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","BK4585":"ETF&股票定投概念","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","BK4534":"瑞士信贷持仓","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4139":"生物科技","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4588":"碎股","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","CERE":"Cerevel Therapeutics Holdings, Inc.","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4581":"高盛持仓"},"translate_title":"Big deal in pharmaceutical industry: Albertville buys Cerevel for $8.7 billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CERE":1,"IMGN":1,"ABBV":0.9},"content_text":"美国生物技术公司艾伯维(ABBV.N)将以87亿美元收购神经科学药物制造商Cerevel Therapeutics(CERE.O)，每股价格为45美元，较其周三的收盘价溢价22%。Cerevel成立于2018年，2020年上市，正在开发治疗阿尔茨海默病、精神病、癫痫、恐慌症和帕金森病等疾病的药物。艾伯维称，Cerevel“强大的”神经科学产品线有望为其增加改变精神科和神经系统疾病护理标准的药物。艾伯维表示，两家公司的董事会已批准该交易，预计将于2024年中期完成，但仍须获得Cerevel股东的批准并满足其他成交条件。消息传出后，Cerevel股价在盘后交易停牌前上涨14%，而艾伯维则下跌了1.3%。艾伯维表示，预计该交易将在2030年开始提振其调整后的每股收益。Cerevel拥有多种处于临床或临床前阶段的研发药物，其中包括Emraclidine，一种治疗精神分裂症和阿尔茨海默病精神病（包括幻觉和妄想等症状）的实验性药物。该药物目前正在老年志愿者中进行第一阶段研究。艾伯维CEO查德·冈萨雷斯（Richard A.Gonzalez）在一份声明中表示：“我们现有的神经科学产品组合以及与Cerevel的合并管道将在未来十年带来重大增长机会。”他还称，艾伯维将利用其深厚的商业能力、国际基础设施以及监管和临床专业知识，为Cerevel的资产组合提供巨大的股东价值和数十亿美元的销售潜力。这笔交易是艾伯维扩大药品管线的最新尝试，其最畅销的治疗药物（如修美乐）面临仿制药的激烈竞争。就在上周，艾伯维同意以近100亿美元收购癌症药物开发商Immunogen(IMGN.O)。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2389601864"}